InSphero

3D InSight™ Microtissues are gold-standard, pharma-validated, preclinical co-culture tissue models for efficacy and toxicology testing with unique uniformity, ease of use and biological functionality.

Microtissue types

• 3D InSight™ Human Liver Microtissues: Have been shown to achieve 2x higher sensitivity for DILI prediction compared to traditional 2D hepatocytes. These advanced 3D liver models, which combine multi-donor diversity with structural and functional robustness, are ideal for drug safety and efficacy testing as well as the study of healthy and diseased liver function.
• 3D InSight™ Animal Liver Microtissues: Rat, dog and cynomolgus monkey microtissues available for translational toxicology and cross-species testing.
• 3D InSight™ Human Islet Microtissues: Their outstanding uniformity makes them perfect for compound screening and mechanistic studies in diabetes research.

Advantages

• Achieve the highest biological relevance in an in vitro co-culture of primary cells
• Test long-term effects of drug exposure in an organotypic, functional tissue model
• Highly reproducible and robust liquid handling in InSphero’s patented Akura™ 96 well plates protect microtissues from accidental aspiration
• Complete turnkey solutions offer lower cost-of-ownership than in-house production

InSphero’s scientists have validated and optimized 3D-cell-based assays and endpoints for several applications within the drug discovery and development cycle, spanning applications from the early phases to post-market in vitro studies. When you purchase 3D InSight™ microtissues or services, you gain access to our proven protocols and experience with these certified applications.

Microtissue types

• 3D InSight™ Human Liver Microtissues: Have been shown to achieve 2x higher sensitivity for DILI prediction compared to traditional 2D hepatocytes. These advanced 3D liver models, which combine multi-donor diversity with structural and functional robustness, are ideal for drug safety and efficacy testing as well as the study of healthy and diseased liver function.
• 3D InSight™ Animal Liver Microtissues: Rat, dog and cynomolgus monkey microtissues available for translational toxicology and cross-species testing.
• 3D InSight™ Human Islet Microtissues: Their outstanding uniformity makes them perfect for compound screening and mechanistic studies in diabetes research.

Advantages

• Achieve the highest biological relevance in an in vitro co-culture of primary cells
• Test long-term effects of drug exposure in an organotypic, functional tissue model
• Highly reproducible and robust liquid handling in InSphero’s patented Akura™ 96 well plates protect microtissues from accidental aspiration
• Complete turnkey solutions offer lower cost-of-ownership than in-house production

3D InSight™ Liver Toxicology Testing is our offer for compound developers looking for highly predictive, reliable and fast-turnaround liver toxicology testing using the market leading, primary 3D liver model, our 3D InSight™ Liver Microtissues. By pooling compound samples from our large customer base into bi-weekly testing runs, InSphero can offer this service at highest quality, fast turnaround and at an attractive price point. Our board-certified toxicologists review every dataset carefully and provide valuable insights to you.

Service types

• 3D InSight™ Liver Toxicology Testing: 14-day exposure, repeat-dose testing of drug-induced liver injury (DILI) on 3D primary human hepatocytes in co-culture with Kupffer and endothelial cells. This 3D InSight™ Liver Microtissue model has been shown to achieve 2x higher sensitivity for DILI prediction compared to traditional 2D hepatocytes.
• Translational Toxicology Consulting using 3D InSight™ Animal and Human Liver Microtissues: To detect potential species-specific safety hazards before an animal study or to investigate hazards appearing in an animal, our board-certified toxicologists advise you, develop study plans and execute complete translational safety studies using our unique 3D models and experience. Available for rat, dog and cynomolgus.

In vitro liver and pancreatic toxicity testing:

• Drug Induced Liver Injury (DILI) Prediction: 7 day or 14 day hepatoxicity studies.
• Mitochondrial Toxicity: assess mitochondrial liabilities and classify compound toxicity.
• Inflammation-mediated Toxicity: Detect potential indirect hepatotoxicity by inducing an inflammatory response.
• CYP-mediated Toxicity: Determine involvement of P450 cytochromes in hepatotoxicity.
• Cholestasis: Predict cholestasis by co-exposure of drugs with bile acids.
• Drug induced Steatosis: Evaluate effects of drug-induced lipid accumulation.
• Apoptosis: Utilize Caspase 3/7 activation as a sensitive marker for hepatotoxicity.
• Omics Profiling: Detect changes in gene and protein expression over time and various dose levels.
• Cross Species Hepatotoxicity studies with human, dog, monkey and rat microtissues

3D InSight™ Tumor Microtissues from Patient-Derived Xenografts (PDX) are custom, assay-ready 3D in vitro tumor models engineered to reflect complex tumor biology without the use of artificial matrices. Ideal for early stage cancer drug efficacy testing and screening applications, these advanced cancer models help bridge the gap between preclinical in-vitro studies and mouse PDX models for subsequent in vivo testing.

Advantages:

• Scalable model in 96w- and soon 384w format enables testing (or even screening) of larger sets of drug candidates or drug combinations
• In vivo-like heterogeneity and primary cell source for increased biological relevance vs cell lines
• Conduct assays for biomarker discovery and disease-oriented drug development using relevant 3D models chosen for genetic alteration or tumor type
• Preselect agents of interest for further preclinical development with an oncology drug discovery tool designed to reduce research costs and optimize human tumor material.
• Highly reproducible and robust liquid handling in InSphero’s patented Akura™ 96 well plates protect microtissues from accidental aspiration

3D InSight™ Islet Microtissues are gold-standard, pharma-validated, preclinical co-culture pancreatic islet models for efficacy and toxicology testing with unique uniformity, ease of use and biological functionality. Re-aggregated using our proprietary technology from primary, isolated islets, this 3D model offers a unique uniformity.

Microtissue products and research services

• 3D InSight™ Human Islet Microtissues
• Research services and discovery partnerships in diabetes T1 and T2: Leveraging our unique 3D models our market-leading expert team develops fit-for-purpose assay pipelines for all major therapeutic strategies in diabetes T1 and T2.

Advantages

• Unmet size uniformity and cellular composition improves assay robustness and data quality
• One microtissue per well, available in 96w and 384w formats
• Test long-term effects of drug exposure in an organotypic, functional tissue model
• Highly reproducible and robust liquid handling in InSphero’s patented Akura™ 96 well plates protect microtissues from accidental aspiration
• Complete turnkey solutions offer lower cost-of-ownership than in-house production

3D InSight™ Islet Microtissues are gold-standard, pharma-validated, preclinical co-culture pancreatic islet models for efficacy and toxicology testing with unique uniformity, ease of use and biological functionality. Re-aggregated using our proprietary technology from primary, isolated islets, this 3D model offers a unique uniformity.

Microtissue products and research services

• 3D InSight™ Human Islet Microtissues
• Research services and discovery partnerships in diabetes T1 and T2: Leveraging our unique 3D models our market-leading expert team develops fit-for-purpose assay pipelines for all major therapeutic strategies in diabetes T1 and T2.

Advantages

• Unmet size uniformity and cellular composition improves assay robustness and data quality
• One microtissue per well, available in 96w and 384w formats
• Test long-term effects of drug exposure in an organotypic, functional tissue model
• Highly reproducible and robust liquid handling in InSphero’s patented Akura™ 96 well plates protect microtissues from accidental aspiration
• Complete turnkey solutions offer lower cost-of-ownership than in-house production

Our scientists have developed islet and liver disease models based on our innovative 3D cell-based technology platforms that closely mimic healthy and diseased human biology. Our fully validated and standardized assay-ready 3D disease models and wide-range of certified applications accelerate your diabetes and fibrosis/NASH drug discovery.